Back | Next |
home / stock / etnb / etnb message board
Subject | By | Source | When |
---|---|---|---|
Oh here is a link for the Chairman | subslover | investorshub | 03/22/2023 4:46:21 PM |
TY sub. In whse & out of battery. | MiamiGent | investorshub | 03/22/2023 3:24:10 PM |
$ETNB: I concur, Sir, on ALL of your | Invest-in-America | investorshub | 03/22/2023 2:37:46 PM |
Hey, dude, it's been a while. I found | subslover | investorshub | 03/22/2023 2:12:12 PM |
$ETNB: Soaring, Boss!!! Will it hold past the | Invest-in-America | investorshub | 03/22/2023 1:53:28 PM |
What a HUGE call. Many congrats to you! | subslover | investorshub | 03/22/2023 12:24:04 PM |
$ETNB 89BIO INC | MiamiGent | investorshub | 03/20/2023 5:33:19 PM |
$15.50 | subslover | investorshub | 02/08/2023 10:13:15 PM |
$14,53 | subslover | investorshub | 02/08/2023 3:59:43 AM |
$14.45. | subslover | investorshub | 02/07/2023 2:32:30 AM |
12 dollars! | subslover | investorshub | 12/23/2022 12:58:34 AM |
89bio Announces Publication of Results of Phase 1b/2a | subslover | investorshub | 12/14/2022 8:57:18 PM |
Finally broke $9.99 after 3 weeks of flirting | subslover | investorshub | 11/12/2022 1:16:53 AM |
$10 test still comin' for us subs buddy choo-choo;) | doogdilinger | investorshub | 10/18/2022 5:30:52 PM |
Huge moe today closed $9.27 up 25% | subslover | investorshub | 10/17/2022 11:45:20 PM |
Don't know but I feel $10.00 is in | subslover | investorshub | 10/12/2022 1:05:20 AM |
Closed at $8.49 for an incredible week's gain. | subslover | investorshub | 10/08/2022 3:58:41 AM |
What happend 2003 OTC? | ollik78 | investorshub | 10/06/2022 9:42:58 PM |
I have a strong feeling that we see | subslover | investorshub | 10/06/2022 2:53:27 PM |
Yes you did brotha and man oh man | doogdilinger | investorshub | 10/06/2022 2:50:20 PM |
News, Short Squeeze, Breakout and More Instantly...
89bio Inc. Company Name:
ETNB Stock Symbol:
NYSE Market:
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...
2024-05-10 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
–Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients– –Expect to initiate ENLIGHTEN-Cirrhosis trial this quarter in MASH patients with compensated cirrhosis (F4)– ...